Papalocal
Loading…
← All news
Health

Nerve-muscle communication failure identified as reversible driver of age-related muscle loss

A University of Missouri study finds that a protein breakdown at the nerve-muscle junction — long assumed to be reliable with age — contributes to sarcopenia, and that partially blocking a second protein can restore strength in animal models.

How does this story make you feel?

For decades, scientists assumed the point where nerves tell muscles to move stays reliable — or even improves — as people age. A study published in The Journal of Clinical Investigation shows that assumption is wrong, and that fixing the breakdown there could one day help the nearly half of adults over 80 who struggle to maintain the muscle strength needed to climb stairs, catch a grandchild, or safely cross a street.

W. David Arnold, executive director of the NextGen Precision Health initiative at the University of Missouri, and his collaborators found that reduced levels of a protein called NaV1.4 impair signaling at the neuromuscular junction — the precise point where a nerve communicates with a muscle to make it contract — as people age. The result is that nerve signals become less effective at triggering muscle fibers, contributing to the condition known as sarcopenia.

A long-held assumption in the field was that the neuromuscular junction remains reliable during aging, and some even suggested it may get better with aging. The significance of this new study is we are showing, in both humans and in animal models, that the neuromuscular junction is failing with aging.— W. David Arnold, executive director, NextGen Precision Health initiative, University of Missouri

Sarcopenia affects roughly 5% to 13% of people aged 60 to 70, rising to up to 50% of those aged 80 or older, according to Harvard Health. It is linked to falls, bone fractures, longer hospital stays, metabolic disorders, cognitive impairment, and loss of independence. Muscle mass naturally declines at about 3% to 5% per decade starting at age 30, and people who do no strength training can expect to lose four to six pounds of muscle per decade.

Previous research into sarcopenia focused on two main culprits: changes within the muscles themselves — chiefly the loss of muscle mass — and the loss of neurons that send movement signals. Arnold spent more than a decade studying whether something was also going wrong in between, at the neuromuscular junction itself.

The discovery did more than identify a new point of failure. It also pointed toward a potential fix. Working with NMD Pharma, a biotechnology company in Denmark, Arnold's team found that partially inhibiting a separate protein called ClC-1 made aging muscles more responsive to nerve signals and improved muscle strength in an animal model.

We identified an important point of failure at the final step in communication between nerves and muscles. And what is perhaps even more exciting is that we showed this failure is potentially reversible.— W. David Arnold, executive director, NextGen Precision Health initiative, University of Missouri

The compound NMD Pharma developed to partially inhibit ClC-1 is called ignaseclant. Arnold was an investigator in a multicenter clinical trial of ignaseclant in patients with Charcot-Marie-Tooth disease, the most common inherited neuromuscular disorder. That trial found improvements across several measures of muscle strength and function, and Arnold presented the topline results at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference. Those trials focused on a different condition, but they provide existing human evidence that targeting ClC-1 can improve aspects of muscle strength.

I realized that in order to make a drug widely available to treat sarcopenia, the first step is better understanding what is causing sarcopenia in the first place.— W. David Arnold, executive director, NextGen Precision Health initiative, University of Missouri

Separately, research published in the journal Gut points to a second, very different avenue: the gut microbiome. Researchers from the Netherlands and Spain found that a gut bacterium called Roseburia inulinivorans is associated with greater muscle strength in people and improved muscle performance in mice. Among older adults in the study, those with detectable levels of R. inulinivorans had 29% greater handgrip strength than those in whom the bacterium could not be detected. In a mouse experiment, animals given R. inulinivorans showed around a 30% increase in forelimb grip strength compared with controls, along with larger muscle fibers and a greater proportion of fast-twitch (type II) fibers — the kind used for short bursts of intense activity.

The researchers note that R. inulinivorans is generally less abundant in older adults than in younger ones — a period that coincides with rising rates of sarcopenia — and suggest the bacterium could potentially be developed into a nutraceutical probiotic. However, they caution that the mouse experiment did not result in permanent colonization of the animals' guts by the human bacterial strains, and that long-term research is needed to establish whether changes in R. inulinivorans levels actually cause changes in muscle function, or whether the relationship runs the other way.

While these pharmacological and microbiome findings develop, established interventions remain the current standard. Harvard Health notes that strength training — using body weight, free weights, elastic bands, or machines — and power training can build and maintain muscle at any age, and that adequate protein, carbohydrates, and healthy fats support muscle growth. People who have never done strength training or who have a chronic condition are advised to consult a doctor before starting.

The neuromuscular junction finding has not yet been tested in older human patients for sarcopenia specifically; that step remains ahead. But the existence of clinical trial data on ignaseclant in a related neuromuscular condition means the path from animal model to human trial is shorter than it would be for a compound with no human safety record at all.

Why it matters — Sarcopenia robs millions of older adults of mobility and independence, and until now had no clear pharmacological target — these findings identify a reversible biological mechanism and a drug candidate already in human trials for a related condition.

⚠ Not yet confirmed

  • R. inulinivorans could be developed into a nutraceutical probiotic aimed at age-related muscle wasting.
  • Ignaseclant could eventually help older adults with sarcopenia.

Reported by futurity.org, health.harvard.edu, newscientist.com, bmjopensem.bmj.com, sciencedaily.com

People in this story

Community

Be the first to comment.

Share this story
Text Email